Short Communication

Parental attitudes and information needs in an adolescent HPV vaccination programme

R Stretch1, SA Roberts2, R McCann3, D Baxter4, G Chambers5, H Kitchener1 and L Brabin*,1

1Academic Unit of Obstetrics and Gynaecology, University of Manchester, Manchester M13 OJH, UK; 2Health Methodology Research Group, University of Manchester, Manchester M13 9PT, UK; 3Greater Manchester Health Protection Unit, Eccles M30 0NJ, UK; 4Public Health Department, Stockport Primary Care Trust, Stockport SK4 1BS, UK; 5Public Health Department, Bury Primary Care Trust, Bury M45 7TA, UK

British Journal of Cancer (2008) 99, 1908–1911. doi:10.1038/sj.bjc.6604766 www.bjcancer.com

In the United Kingdom, routine human papillomavirus (HPV) vaccination for 12–13-year-old girls to prevent cervical cancer has begun. The highest possible vaccine uptake is required to achieve maximum impact on future cancer incidence and to ensure cost effectiveness (Goldhaber-Fiebert et al, 2008). Two parental acceptability studies in the UK anticipated an uptake of about 80% (Brabin et al, 2006; Marlow et al, 2007a), which would be similar to the coverage achieved by the cervical screening programme. As those girls who are not vaccinated may include some who would not take advantage of future cervical screening, reducing non-acceptance is important (Jit et al, 2008).

A school-based programme increases the possibility of high coverage, but the acceptability of vaccinating adolescents against a sexually transmitted infection remains uncertain, and the general public is relatively uninformed, or even misinformed, about cervical cancer and its prevention (Friedman and Shepheard, 2007; Marlow et al, 2007b). We assessed vaccine acceptability in a feasibility study ahead of the national vaccine programme. Two primary care trusts (PCTs) in Greater Manchester that offered Cervarix (GlaxoSmithKline, Rixensart, Belgium) to girls attending 36 secondary schools achieved a 71% uptake of the first HPV vaccine dose (Brabin et al, 2008). Here we present the results of a parental questionnaire survey shortly after the second dose, which focussed on factors that had influenced the parents’ vaccine decision and included a small group of respondents who had declined vaccination.

MATERIALS AND METHODS

The North Manchester NHS Research Ethics Committee approved the study. Cervarix was offered at 0, 1 and 6 months to 2817 girls aged 12–13 years between October 2007 and July 2008 (Brabin et al, 2008). In the covering letter, parents were informed that the funding source was GlaxoSmithKline and that Cervarix was one of two licensed vaccines; it explained that the vaccine for the future national immunisation programme and the policy for vaccinating older girls had not yet been determined. Parents received information about cervical cancer and the vaccine, a flier summarising the content of an educational film for girls (Vallely et al, 2008), details of parent evenings and a separate consent form for the follow-up research questionnaire. Information evenings provided an overview of HPV vaccines and the study aims; the educational film was shown, followed by a question and answer session facilitated either by school nurses or by a consultant in communicable diseases.

Primary care trusts forwarded to the research team the names and addresses of parents who had agreed to be sent questionnaires. The questionnaire asked about factors that may have influenced vaccine consent, including socio-demographic characteristics; the information sheet; parent information evenings; other information sources; concerns about vaccine safety and efficacy; and their child’s wish for vaccination and sexual issues. Responses were mainly measured using a Likert scale appropriate to the question asked. Proportions were summarised according to whether consent was given (‘consenters’) or refused (‘refusers’), and Fisher’s exact tests were used to assess the significance of differences between groups. An open question asked parents who had attended an information session to state whether, and how, this had influenced their vaccine decision. The responses were analysed semi-qualitatively.

RESULTS

In all, 38% (1084) of the 2853 eligible parents consented to be contacted and 60% (651) of these returned a questionnaire, including 605 consenters and 46 refusers (20% of the non-vaccinated group). There were no significant differences in the ages, ethnicity, religion or free school meal entitlement between
consenters and refusers in either PCT. Compared with the general population, fewer questionnaires were returned by parents of children receiving free school meals (6 vs 13%) or non-white parents (7 vs 10%), and only 17 were non-Christian.

In total, 97% (628) of the parents had read the information sheet. Compared with consenters, refusers were less satisfied with the level of detail provided, were more likely to state that it did not answer their questions and were largely uninfluenced by its contents (P < 0.001) (Table 1). Parents were least clear about the length of protection conferred and how the vaccine prevented cervical cell changes (Table 2). Refusers were more likely than consenters to remain unclear about the results of clinical trial data (16 vs 5%; P = 0.01) and HPV types (14 vs 3%; P = 0.004).

The 20% (128) of parents who attended an information evening comprised 32% (14) refusers and 19% (114) consenters (P = 0.049). Of the 90% (115) who expressed their view on the evening, 26% (30) stated that it had no influence on their vaccine decision. Some parents valued the opportunity to talk to a health professional for ‘independent’ advice and to hear more detailed information, explained in a way they understood. They liked to hear the views of other parents, which introduced them to new issues, and found the discussions useful and enjoyable. Predominantly, parents used words such as ‘reassured’, ‘confirmation’ and ‘confidence’, although for refusers this generally signified confirmation that other parents shared their reservations.

In all, 33% (213) of the parents gained information on the vaccine from television, 24% (152) from newspapers, 18% (113) from the internet and 6% (100) from a healthcare provider. Friends and relations (14%), radio (13%) and magazines (6%) were less often cited. Only 14% (88) based their decision solely on the information provided by the vaccine programme. Refusers actively sought additional information more often than consenters, citing the internet or health professionals as sources (48 vs 27%, P = 0.006).

More refusers than consenters had concerns about vaccine safety in general, side effects and booster doses (Table 3). Compatibility of the two available vaccines worried 57% (26) of refusers but only 16% (94) of consenters (P < 0.001). Asked whether the HPV vaccine would encourage their child to become more sexually active, 77% (494) responded ‘not at all’, 19% (124) ‘a little’ and 4% (21) ‘quite’ and 1% (3) were ‘very’ concerned.

Table 1 Respondent’s view of the information sheet

|                  | Consenters |            | Refusers |            | P-value |
|------------------|-----------|------------|----------|------------|---------|
|                  | Missing   | n %        |          | n %        |         |
| Did you find the information sheet easy to read? | Yes | 404 69 | 29 67 | 0.784 |          |
|                  | Mostly    | 26 158 27 | 12 28   |            |         |
|                  | Partly    | 20 4       | 2 5     |            |         |
| Did it give the level of detail you wanted? | Too little | 65 11 20 47 | <0.001 |          |
|                  | The right amount | 29 511 88 23 53 | |         |
|                  | Too much  | 3 1        | 0 0     |            |         |
| Did you find the information sheet answered your questions? | Yes | 239 41 5 12 | <0.001 |          |
|                  | Mostly    | 29 285 49 | 15 35   |            |         |
|                  | Partly    | 52 9       | 17 39   |            |         |
|                  | No        | 3 1        | 6 14    |            |         |
| Did the information sheet influence your decision? | A lot | 79 14 2 5 | <0.001 |          |
|                  | Quite a lot | 34 238 41 | 9 21    |            |         |
|                  | A little  | 190 33 17 41 | |         |
|                  | Not at all | 68 12 14 33 | |         |

* Fisher’s exact test.

Refusers were more likely to be ‘very’ or ‘quite’ concerned (11% (5) vs 3% (19); P = 0.021).

In addition, 97% (628) of parents reported discussing the vaccine with their daughters. Asked whether their daughters wished to be vaccinated, consenters and refusers, respectively, responded ‘Yes’ [83% (487) vs 19% (8)]; ‘No’ [4% (25) vs 50% (21)]; ‘It was not her decision’ [11% (63) vs 29% (12)]; or ‘Don’t Know’ [2% (11) vs 2% (1)] (P < 0.001). They did not differ with regard to whether boys should be vaccinated. Altogether 52% (328) said ‘Yes’, 5% (33) said ‘No’, 32% (203) would ‘Leave it to the experts to decide’ and 11% (72) ‘Didn’t Know’.

DISCUSSION

Although parents who responded were not familiar with HPV vaccination, the information they received through PCTs only partly influenced their vaccine decision. They mainly sought reassurance about vaccine safety, but as the vaccine is new and phase 4 trials are ongoing doubts about its long-term safety cannot

Table 2 Parental assessment of the clarity of the facts in the information sheet

| Facts | Missing | Consenters | Refusers | P-value  |
|-------|---------|------------|----------|----------|
|       | n %     | n %        |          |          |
| HPV is the main cause of cervical cancer | Very clearly | 285 49 22 50 | 1 | |
|       | Clearly  | 30 283 49 22 50 | | |
|       | Not clearly | 9 2 0 | 0 | |
| Adolescents are at risk of HPV when they start having sex | Very clearly | 284 49 27 62 | 0.24 | |
|       | Clearly  | 31 279 49 16 36 | | |
|       | Not clearly | 13 2 1 | 2 | |
| Vaccine prevents HPV 16 and 18 | Very clearly | 258 45 20 46 | 0.004 | |
|       | Clearly  | 32 301 52 18 41 | | |
|       | Not clearly | 16 3 6 14 | | |
| The vaccine prevents changes to cervical cells | Very clearly | 155 27 8 19 | 0.069 | |
|       | Clearly  | 34 354 62 25 58 | | |
|       | Not clearly | 65 11 10 23 | | |
| The vaccine provides protection for at least 5 years | Very clearly | 165 29 13 30 | 0.32 | |
|       | Clearly  | 34 310 54 19 44 | | |
|       | Not clearly | 99 17 11 26 | | |
| Condoms do not offer 100% protection against HPV | Very clearly | 218 38 15 37 | 0.97 | |
|       | Clearly  | 35 304 53 23 56 | | |
|       | Not clearly | 53 9 3 7 | | |
| Women will still need to go for cervical smears | Very clearly | 265 46 17 43 | 0.81 | |
|       | Clearly  | 37 269 47 21 52 | | |
|       | Not clearly | 40 7 2 5 | | |
| The vaccine does not protect if you already have HPV 16/18 | Very clearly | 212 37 14 35 | 0.58 | |
|       | Clearly  | 42 301 53 24 60 | | |
|       | Not clearly | 56 10 2 5 | | |
be fully answered. As long as safety remains an important issue, adolescent HPV vaccine coverage may, like the measles, mumps and rubella (MMR) vaccine (Smith et al., 2007), not reach the desired level, or that achieved for most infant vaccines. Of concern is the fact that 50% of refusers stated their daughters did not wish to be vaccinated because we do not know whether these girls will take advantage of cervical screening in future.

This is the first study to address parental acceptance of adolescent HPV vaccination within a vaccine programme. Inevitably, it is likely that those responding over-represent the more engaged, articulate parents with stronger views. A return rate of 60%, representing a quarter of the general population, is comparable to telephone surveys on HPV acceptability (Constantine and Jerman, 2007; Ogilvie et al., 2007) and higher than a Dutch postal survey (Lensink et al., 2008). Parents who do not return questionnaires may also be less responsive to a vaccine invitation. A recent study of 14-year-old Belgian adolescents reported lower general vaccine coverage rates for children of single, divorced parents and larger families (≥4 children) (Vandermeulen et al., 2008). The sample did include active refusers (7% of the sample compared with 8% of the population) who tend to be better educated and may hold strong beliefs, but we do not have any information about those who did not respond to the vaccine invitation, and more work is required to understand this group.

Dempsey et al. (2006) reported no effect of written information on HPV vaccine acceptability. We further report that information evenings were attended by a minority of parents, with refusers most likely to attend, whose views were not substantially altered as a result. The literature on childhood vaccination shows that parents who believe in vaccination tend to comply with, rather than make, an informed decision. (Tickner et al., 2007). Worries about MMR have increased public scepticism; therefore, health professionals giving information to parents need to be well prepared with robust, up-to-date information on vaccine safety and other issues. Some refusers cited concerns about vaccine compatibility. This arose from a perception that a quadrivalent must be inherently ‘better’ than a bivalent vaccine, especially as other countries had already selected it. Misinterpretation of the licensing process led to parents waiting to see if the quadrivalent vaccine would be selected for the national programme, even though their daughters might not be eligible (i.e. if there were no catch-up programme). Tailored written information on safety issues could also be prepared, but parents may have taken a decision based on beliefs and attitudes that are difficult to modify.

CONCLUSIONS

Despite some unease about the safety of HPV vaccination, most parents who responded wished to protect their daughters from cervical cancer and comply with vaccine recommendations. Although there is no evidence of bias, the responders represent a quarter of the population in two PCTs; hence, caution is needed in extrapolating the results to the general population. It remains uncertain whether HPV vaccination coverage will exceed cervical screening coverage. Parents may listen to health professionals, who should aim to raise the uptake by communicating the latest scientific data to refusers and dispelling misperceptions about the vaccine.

ACKNOWLEDGEMENTS

GlaxoSmithKline provided the research grant and vaccine. Dr Brabin is funded by The Max Elstein Trust.

REFERENCES

Brabin L, Roberts SA, Farzaneh F, Kitchener HC (2006) Future acceptance of adolescent human papillomavirus vaccination: a survey of parental attitudes. Vaccine 24: 3087 – 3094. DOI:10.1016/j.vaccine.2006.01.048

Brabin L, Roberts SA, Stretch R, Baxter D, Chambers G, Kitchener H, McCann R (2008) Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study. BMJ 336: 1056 – 1058. DOI:10.1136/bmj.39541.534109.BE

Constantine NA, Jerman P (2007) Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 40: 108 – 115. DOI:10.1016/j.jadohealth.2006.10.007

Dempsey AF, Zimet GD, Davis RL, Koutsy L (2006) Factors that are associated with parental acceptance of human papillomavirus vaccine: a randomized intervention study of written information about HPV. Pediatrics 117: 1486 – 1493. DOI:10.1542/peds.2005-1381

Friedman AL, Shephard H (2007) Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV: findings from CDC focus group research and implications for practice. Health Educ Behav 34: 471 – 485. DOI:10.1177/1090198106292022

Goldhaber-Fiebert JD, Stout NK, Salomon JA, Kuntz KM, Goldie SJ (2008) Cost-effectiveness of cervical cancer screening with human papillomavirus DNA testing and HPV-16,18 vaccination. J Natl Cancer Inst 100: 308 – 320. DOI:10.1093/jnci/djn019

Jit M, Yoon Hong C, Edmunds WJ (2008) Economic evaluation of human papillomavirus vaccination in the United Kingdom. BMJ 337: a769. DOI:10.1136/bmj.a769

Lensink CH, Gerrits MMJG, Melchers WJG, Massuger LFAG, Van Hamont D, Bekkers RLM (2008) Parental acceptance of human papillomavirus vaccines. Eur J Obstet Gynecol Reprod Biol 137: 103 – 107
Marlow LAV, Waller J, Wardle J (2007a) Parental attitudes to pre-pubertal HPV vaccination. *Vaccine* 25: 1945 – 1952

Marlow LAV, Waller J, Wardle J (2007b) Public awareness that HPV is a risk factor for cervical cancer. *Br J Cancer* 97: 691 – 694. DOI:10.1038/sj/bjc6603927

Ogilvie GS, Remple VP, Marra F, McNeil SA, Naus M, Pielak KL, Ehlen TG, Dobson SR, Money DM, Patrick D (2007) Parental intention to have daughters receive the human papillomavirus vaccine. *CMAJ* 177: 1506 – 1512

Smith A, Yarwood J, Salisbury DM (2007) Tracking mothers’ attitudes to MMR immunization 1996 – 2006. *Vaccine* 25: 3996 – 4002. DOI:10.1016/j.vaccine.2007.02.071

Tickner S, Leman PJ, Woodcock A (2007) ‘It’s just the normal thing to do’: exploring parental decision-making about the ‘five-in-one’ vaccine. *Vaccine* 25: 7399 – 7409. DOI: 10.1016/j.vaccine.2007.08.008

Vallely LA, Roberts S, Kitchener H, Brabin L (2008) Informing adolescents about HPV vaccination. What will parents allow? *Vaccine* 26: 2203 – 2210. DOI:10.1016/j.vaccine.2008.02.055

Vandermeulen C, Roelants M, Theetan H, Depoorter A-M, Van Damme P, Hoppenbrouwers K (2008) Vaccination coverage in 14-year-old adolescents: documentation, timeliness, and sociodemographic determinants. *Pediatrics* 121: e428 – e434. DOI:10.1542/peds.2007-1415